Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;334:105-106 (20 January), doi:10.1136/bmj.39092.388796.80
Better access to antiretroviral therapy and isoniazid prophylaxis offer new opportunities for control
| The first 150 words of the full text of this article appear below. |
In most countries with limited resources the epidemics of HIV and tuberculosis continue to grow. GOTOBUTTON endnote1 (1) Even with optimal treatment of active tuberculosis, the absolute number of tuberculosis cases will continue to rise if the HIV epidemic is not controlled.1 In this week's BMJ, Zar and colleagues report a randomised controlled trial performed in South Africa on the effect of isoniazid prophylaxis on mortality and the incidence of tuberculosis in children infected with HIV.2 The results of this study suggest that isoniazid prophylaxis may be an effective public health intervention to reduce mortality in HIV infected children in settings with a high prevalence of tuberculosis.2
Today, antiretroviral therapy programmes also offer new opportunities to control tuberculosis.3 4 5 Highly active antiretroviral therapy was shown to decrease the incidence of tuberculosis in HIV positive people by 70% in South Africa4 and 80% in Brazil.5 Although antiretroviral therapy is likely to
Robert Colebunders, head ( bcoleb@itg.be)1, Ludwig Apers, Clinician1, Greet Dieltiens, epidemiologist2, William Worodria, clinician3
1 HIV/STD Unit, Clinical Sciences Department, Institute of Tropical Medicine, 2000 Antwerp, Belgium, 2 Epidemiology Unit, Public Health Department, Institute of Tropical Medicine, 3 HIV/STD Unit, Clinical Sciences Department, Infectious Diseases Institute, Kampala, Uganda